#AHA22 Learning Studios and Roundtables
Plan your schedule now with this comprehensive list of educational sessions during Scientific Sessions 2022.
Learning Studios current as of Oct. 14, 2022
Cardiac Myosin Inhibition, and its Role in the Landscape of Symptomatic NYHA Class II-III Obstructive HCM
Saturday, Nov. 5 | 9:30-10:15 a.m. | Learning Studio I
Supporter: Bristol-Myers Squibb
Conversations in Cholesterol Efflux: How Can We Harness its Cardioprotective Potential?
Saturday, Nov. 5 | 11-11:45 a.m. | Learning Studio I
Supporter: CSL Behring, LLC
Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
Saturday, Nov. 5 | 11-11:45 a.m. | Learning Studio II
Supporter: Boehringer Ingelheim Corporation
Help Your MI Patients Achieve Lower LDL-C and Reduce the Risks of Another MI
Saturday, Nov. 5 | 12:30-1:15 p.m.| Learning Studio I
Supporter: Amgen, Inc.
Expert Perspectives on the Management of Patients With CAD and/or PAD
Saturday, Nov. 5 | 12:30-1:15 p.m.| Learning Studio II
Supporter: Janssen Pharmaceuticals, Inc.
Rethinking the Approach: Management of Elevated LDL-C in Patients With ASCVD
Saturday, Nov. 5 | 1:45-2:30 p.m.| Learning Studio I
Supporter: Novartis Pharmaceutical Corporation
Getting to the Heart of the Matter: Management of CV Risk in Patients With CKD Associated With T2D
Saturday, Nov. 5 | 1:45-2:30 p.m.| Learning Studio II
Supporter: Bayer HealthCare Pharmaceuticals Inc.
Hiding in Plain Sight: Identification and Management of ATTR-CM Patients
Saturday, Nov. 5 | 3-3:45 p.m. | Learning Studio I
Supporter: Pfizer Inc.
Solving the Heart Attack Crisis With Next Generation Plaque Analysis
Saturday, Nov. 5 | 3-3:45 p.m. | Learning Studio II
Supporter: Elucid BioImaging, Inc.
Is the Burden of Symptomatic Chronic HFrEF Inevitable? Defining and Recognizing Early Signs or Symptoms of WHF
Sunday, Nov. 6 | 9:30-10:15 a.m. | Learning Studio II
Supporter: Cytokinetics, Inc.
How Can Twice-Yearly*LEQVIO Help Certain ASCVD Patients Who Are Overburdened by the Daily Demands of their Treatment Plan? *After 2 Initial Doses
Sunday, Nov. 6 | 11-11:45 a.m. | Learning Studio I
Supporter: Novartis Pharmaceutical Corporation
Changing Views on Rhythm Control: Is Earlier Better for Improving Outcomes in AF Patients?
Sunday, Nov. 6 | 11-11:45 a.m. | Learning Studio II
Supporter: Sanofi
Targeting LDL-C in ASCVD Patients: Are We There Yet?
Sunday, Nov. 6 | 12:15-1 p.m. | Learning Studio I
Supporter: Amgen, Inc.
Treatment Considerations for Patients With HFrEF and Select Updates From the 2022 HF Guideline
Sunday, Nov. 6 | 12:15-1 p.m. | Learning Studio II
Supporter: Merck
Fostering the Future of Hispanic Health
Sunday, Nov. 6 | 3:30-4:15 p.m. | Learning Studio I
Supporter: American Heart Association & National Hispanic Latino Cardiovascular Collaborative (NHLCC)
The Role of Antiarrhythmic Drugs in Early Rhythm Control and the Management of Atrial Fibrillation
Sunday, Nov. 6 | 3:30-4:15 p.m. | Learning Studio II
Supporter: AHA-Lifelong Learning
Treating Recurrent Pericarditis and Preventing Recurrence
Monday, Nov. 7 | 9:30-10:15 a.m. | Learning Studio I
Supporter: Kiniksa Pharmaceuticals
Roundtables
HCM: Understanding the Patient Journey
Saturday, Nov. 5 | 9:30-10 a.m. | Heart Theater II
Supporter: AHA—HCM Roundtable
Latest Hypertension Consensus Publications
Saturday, Nov. 5 | 11-11:30 a.m. | Heart Theater II
Supporter: Medtronic
CCM Therapy: Your Patients Want to Feel Better
Saturday, Nov. 5 | 12:30-1 p.m. | Heart Theater II
Supporter: Impulse Dynamics
Operationalizing CCM® Therapy
Sunday, Nov. 6 | 11-11:30 a.m. | Heart Theater II
Supporter: Impulse Dynamics
NHLBI Company Showcase
Sunday, Nov. 6 | 3:30-5 p.m. | Heart Theater II
Supporter: NHLBI Showcase
